Portola Enters Agreement With Xarelto Manufacturer Bayer Amid Lawsuit Increases

March 26, 2016 – – BloodThinnerHelp.com reports on Portola Pharmaceuticals’ announcement concerning a clinical collaboration with Bayer. Portola announced that it has decided to enter a collaboration with the manufacturers of Xarelto to include its Factor Xa inhibitor rivaroxaban in a clinical development program in Japan. Portola is developing an FDA designated breakthrough therapy called andexanet alfa to reverse anticoagulation in patients taking Factor Xa inhibitors such as Xarelto.

Terms of Portola’s agreement with Bayer include an upfront payment of $5 million and may include a milestone payment should Japanese MHLW (Ministry of Health Labour and Welfare) approve andexanet alfa as an antidote for Xarelto, according to statements from Portola. The group also entered into separate agreements with Bayer and Janssen Pharmaceuticals, Inc. to support studies of the antidote in the U.S. and Europe.

While this may be good news for future users of Xarelto, thousands of patients who have already used Xarelto have claimed to suffer adverse side effects including uncontrolled bleeding, which Portola’s new investigational drug is expected to stop.

An internal bleed can occur in many parts of the body. Internal bleeding occurs when damage to an artery or vein causes blood to leak out and pool in other areas of the body.

Other side effects plaintiffs claim to have suffered include heart attack, stroke, gastrointestinal bleeding and pulmonary embolisms. The alleged side effects are the crux of almost 3,000 lawsuits that have been filed federally in the U.S. Those cases have been consolidated into a multidistrict litigation panel in Eastern Louisiana. Those filed in the commonwealth of Pennsylvania have been consolidated by the Philadelphia Court of Common Pleas into a mass tort program which has reached 620 cases.

While those cases await trial, Attorney Joseph Osborne is working to ensure that those who believe they have been negatively affected by the blood-thinning drug are able to explore their legal rights. Qualifying individuals may be entitled to legal action and financial compensation. Osborne is currently offering free legal consultations to affected parties.

For more information about Xarelto, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008905